关于开发针对eumycetoma的新型抗真菌剂的最新情况
David J Chandler1,2, Alexandro Bonifaz3, Wendy W J van de Sande4
1Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, United Kingdom.
Frontiers in pharmacology
|June 5, 2023
概括
对于eumycetoma,一种目前治疗结果不佳的真菌感染,迫切需要新的治疗方法. 本综述探讨了管理这种慢性皮下菌根的新兴治疗策略和未来挑战.
科学领域:
- 医学真菌学 医学真菌学
- 传染性疾病 传染性疾病
- 药物开发 药物开发
背景情况:
- 湿瘤是一种被忽视的热带疾病,由真菌引起,导致慢性皮下感染.
- 目前的抗真菌治疗在很大程度上是无效的,往往需要激进的手术干预,如肢体截肢.
- 对于eumycetoma的新和有效的治疗选择存在着至关重要的未满足的需求.
研究的目的:
- 对eumycetoma的现有和新兴治疗策略进行审查.
- 总结一下新抗真菌疗法开发的最新进展.
- 讨论eumycetoma治疗研究中的挑战和未来方向.
主要方法:
- 关于eumycetoma治疗的临床前和临床研究的文献综述.
- 对药物发现管道和治疗方法的分析.
- 综合有关治疗有效性,安全性和挑战的信息.
主要成果:
- 现有治疗方法的疗效有限,突出显示需要新的干预措施.
- 几种新型抗真菌剂和药物输送系统正在调查中.
- 挑战包括耐药性,透到受感染的组织和治疗时间.
结论:
- 开发有效治疗eumycetoma仍然是一个重大挑战.
- 创新的治疗策略对于改善患者的治疗结果和减少对手术的需要至关重要.
- 持续的研究和开发对于对抗这种令人衰弱的真菌感染至关重要.
相关概念视频
01:28Fungal Phylum Microsporidia
43
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
43
01:29Fungal Group Zygomycota
58
Zygomycota, previously classified as a distinct fungal group, are primarily terrestrial, saprophytic molds that play a crucial role as decomposers. Recent phylogenetic studies have revealed that these fungi are now divided into two major clades — Mucoromycota, which includes many symbiotic species, and Zoopagomycota, which primarily consists of parasitic and pathogenic fungi. These groups exhibit distinct ecological roles and reproductive strategies while sharing key structural and...
58